Ohio State University cohort: rs1800795 SNP is associated with distant metastases of primary breast cancer.

<p>Graphs show the proportions of homozygous dominant, heterozygous, and homozygous recessive alleles at (A) rs1800795 and (B) rs4506565 from primary breast cancer patients. Total patient numbers shown represent non-missing values. <i>P</i> values represent test for overall association between SNPs and case or control status, and were determined using ANOVA.</p

All Ohio State University breast cancer cases develop metastases within ten years from primary diagnosis.

<p>Kaplan-Meier curve shows changes in proportion of metastasis-free breast cancer cases as they develop metastasis after primary diagnosis. “CC”: red dotted line; “CG”: blue dotted-solid line, and “GG”: black solid line.</p

VUMC patient demographics.

<p>VUMC patient demographics.</p

Ohio State University cohort: Patient and tumor characteristics by rs1800795 status.

<p>Ohio State University cohort: Patient and tumor characteristics by rs1800795 status.</p

VUMC cohort: rs1800795 and rs4506565 SNPs are associated with distant metastases.

<p>Graphs show the proportions of homozygous dominant, heterozygous and homozygous recessive alleles at (A) rs1800795 and (B) rs4506565. Total patient numbers shown represent non-missing values. Six controls had missing rs1800795 genotype information. One case and eight controls had missing rs4506565 genotype information. Statistical analyses show ANOVA test of overall association between SNPs and case or control status.</p

Ohio State University cohort: Conditional logistic regression model for rs1800795 SNP association with breast cancer metastases among non-Hispanic whites only.

<p>Ohio State University cohort: Conditional logistic regression model for rs1800795 SNP association with breast cancer metastases among non-Hispanic whites only.</p

Ohio State University cohort: Conditional logistic regression model for rs1800795 SNP association with breast cancer metastases.

<p>Ohio State University cohort: Conditional logistic regression model for rs1800795 SNP association with breast cancer metastases.</p

Ohio State University cohort: Patient and tumor characteristics.

<p>Ohio State University cohort: Patient and tumor characteristics.</p

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Atezolizumab plus bevacizumab has become frontline therapy for unresectable HCC. The compatibility of atezolizumab/bevacizumab with liver-directed RT has not been reported. Methods: HCC patients treated with liver-directed RT and atezolizumab/bevacizumab between 1/2020&ndash;11/2021 were included. Toxicity and outcomes were retrospectively recorded. For ALCs, we matched the analysis to a previously cohort of RT-treated HCC patients who did not receive atezolizumab/bevacizumab. Survival and time-to-liver-failure were analyzed using Kaplan&ndash;Meier. Results: Of 21 patients, with a median follow-up of 9.5 months, the median OS was 16.1 months. Post-RT, all patients had reduced tumors or treatment response. There were no &ge;Grade 3 RT-related toxicities. Autoimmune complications occurred in two patients (9.5%), and GI bleeding in three patients (14.3%). Liver function remained stable post-RT. There was a marked decrease in ALCs immediately post-RT (post-RT/pre-RT ratio 47.3%, p &lt; 0.0001), restored by 1 month to pre-treatment baseline (1-month post-RT/pre-RT ratio 95.1%, n.s.). Compared to HCC patients treated with RT alone, post-RT ALC recovery was faster with atezolizumab/bevacizumab (p = 0.009). Conclusion: In this first reported experience of RT with modern systemic therapy for HCC, combination therapy is safe and well-tolerated. As a favorable prognosticator, there appears to be faster recovery of ALC among patients who received RT with atezolizumab/bevacizumab